Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: Connor26 who wrote (94963)	9/25/2003 8:13:02 AM
From: Findit	Read Replies (2) \| Respond to of 208838

CRXL may do well today on news. Not in this time. AMSTERDAM -(Dow Jones)- Crucell N.V. (CRXL) and Novavax, Inc. (NVAX) said Thursday that they have entered into a license agreement to offer vaccine manufacturing services for clinical grade materials on Crucell's proprietary PER.C6 technology. In addition, Novavax will use Crucell's PER.C6 technology for research on two targeted vaccines. Under the terms of the agreement, Crucell will receive upfront and annual payments, as well as royalties on contract manufacturing sales by Novavax. Further financial details were not disclosed. Novavax will offer manufacturing services to governments and academia for inactivated, subunit and attenuated viral vaccines produced on Crucell's proprietary PER.C6(TM) production technology. PER.C6 technology is considered an attractive production platform for many of these types of vaccines, which make up the largest segment of the vaccine market, with billions of doses sold per year. Crucell's thirty PER.C6 licensees cover the full range of biopharmaceuticals, including recombinant vaccines, classical vaccines, gene therapy vectors, monoclonal antibodies, therapeutic proteins and veterinary vaccines. Crucell offers manufacturing services on PER.C6 technology for monoclonal antibodies and therapeutic proteins through DSM Biologics and for recombinant vaccines and gene therapy vectors through Molecular Medicine, LLC. (END) Dow Jones Newswires September 25, 2003 02:54 ET (06:54 GMT) BTW - HEC had a 500 share trade in PM for .70. Jim